• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 957127 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414689255 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414689255 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Acadia Pharmaceuticals Bullish Moving Average Crossover Alert (ACAD)

Published on Thu, 05/15/2014 - 13:19
By Peter Chu

Today, shares of Acadia Pharmaceuticals (NASDAQ:ACAD) have crossed bullishly above their 10-day moving average of $19.04 on a volume of 954K shares. This may provide swing traders with an opportunity for a long position, as such a crossover often suggests higher prices in the near term.

Acadia Pharmaceuticals share prices have moved between a 52-week high of $32.00 and a 52-week low of $11.81 and are now trading 63% above that low price at $19.23 per share. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 2.6%.

Acadia Pharmaceuticals has overhead space with shares priced $19.23, or 42.1% below the average consensus analyst price target of $33.20. The stock should run into initial resistance at its 50-day moving average (MA) of $22.47 and subsequent resistance at its 200-day MA of $23.17.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

DENTSPLY International (XRAY) Breaks Thr...

Shares of DENTSPLY International (NASDAQ:XRAY) have bullishly opened above the pivot of ...

Stock Investors Sell Off Shares of Stone...

Stone Energy (NYSE:SGY) is one of today's biggest movers, down 4.4% to $24.27. The S&P ...

Chart Industries Makes a Move: Down 4.5%...

Chart Industries (NASDAQ:GTLS) is one of today's notable stocks in decline, down 4.5% t ...

Next Resistance Level for Ameren (AEE) i...

Shares of Ameren (NYSE:AEE) have bullishly opened above the pivot of $41.38 today and h ...

Wisconsin Energy (WEC) Crosses Pivot Poi...

Shares of Wisconsin Energy (NYSE:WEC) have bullishly opened above the pivot of $48.35 t ...

Telecom Argentina Makes a Move: Up 4.5%...

Telecom Argentina (NYSE:TEO) is a company whose shares are active, trading 4.5% higher ...

Rosetta Resources Makes a Move: Down 4.6...

Rosetta Resources (NASDAQ:ROSE) is a company whose shares are active, trading 4.6% lowe ...

Dominion Resources (D) Approaches New Up...

Shares of Dominion Resources (NYSE:D) have bullishly opened above the pivot of $70.23 t ...